CAS: 1315330-17-6
Brand | Product data | Purity | Price range | Estimated delivery |
---|---|---|---|---|
3-(6,7-Dimethoxyquinazolin-4-yloxy)-N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide REF: 3D-QCC33017CAS: 1315330-17-6 | Min. 95% | To inquire | Wed 15 Jan 25 | |
TL02-59 REF: TM-T13186CAS: 1315330-17-6 | 95.63% | 69.00 €~903.00 € | Wed 05 Feb 25 |
3-(6,7-Dimethoxyquinazolin-4-yloxy)-N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide
CAS:1315330-17-6
3-(6,7-Dimethoxyquinazolin-4-yloxy)-N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide is a potent inhibitor of the human TRPV2 ion channel. It has been shown …
Formula:
C32H34F3N5O4
Purity:
Min. 95%
Molecular weight:
609.6 g/mol
Ref: 3D-QCC33017
10mg | To inquire | ||
25mg | To inquire | ||
50mg | To inquire | ||
100mg | To inquire |
Estimated delivery in United States, on Wednesday 15 Jan 2025
TL02-59
CAS:1315330-17-6
TL02-59: Fgr inhibitor (IC50=0.03nM), also targets Lyn (0.1nM), Hck (160nM), halts acute myelogenous leukemia growth.
Formula:
C32H34F3N5O4
Purity:
95.63%
Color and Shape:
Solid
Molecular weight:
609.64
- Inhibitors
- Apoptosis
- Tyrosine Kinase/Adaptors
- Hck
- See more categories
- Src
Ref: TM-T13186
1mg | 69.00 € | ||
5mg | 130.00 € | ||
10mg | 205.00 € | ||
25mg | 346.00 € | ||
50mg | 493.00 € | ||
100mg | 671.00 € | ||
200mg | 903.00 € | ||
1mL*10mM (DMSO) | 169.00 € |
Estimated delivery in United States, on Wednesday 5 Feb 2025